Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05981365 · ClinicalTrials.gov registry record · Phase 1
Voxelotor CYP and Transporter Cocktail Interaction Study
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT05981365 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 44 participants.
The verdict
NCT05981365, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are metabolized by cytochrome enzymes. The substrates used in this study are FDA approved medications). The study will help to determine the safety and tolerability of the study drugs taken together, as well as the pharmacokinetics (PK) on how your body processes and responds to the combination of the study drug and substrates. Although these drugs are FDA approved, their use in this study is experimental.
Interventions
- DRUG Omeprazole
- DRUG Bupropion
- DRUG Voxelotor
- DRUG Repaglinide
- DRUG Flurbiprofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2023-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05981365
The ClinicalTrials.gov registry entry for NCT05981365 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Omeprazole is the first listed.
NCT05981365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05981365 about?
NCT05981365 is a clinical study titled "Voxelotor CYP and Transporter Cocktail Interaction Study". This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are metabolized by cytochrome enzymes. The substrates used in this study are FDA ap...
What is the current status of trial NCT05981365?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-04-17. Estimated completion is 2023-10-04.
What interventions are being tested in trial NCT05981365?
The interventions under investigation include: Omeprazole (DRUG), Bupropion (DRUG), Voxelotor (DRUG), Repaglinide (DRUG), Flurbiprofen (DRUG).
Who is sponsoring clinical trial NCT05981365?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.